0 CHECKOUT

Haemophilus Influenzae Type b Infections - Pipeline Review, H1 2015

  • ID: 3308767
  • June 2015
  • 64 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Biological E. Limited
  • LG Life Sciences, Ltd.
  • Novartis AG
  • Nuron Biotech, Inc.
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • MORE

Haemophilus Influenzae Type b Infections - Pipeline Review, H1 2015

Summary

This, ‘Haemophilus Influenzae Type b Infections - Pipeline Review, H1 2015’, provides an overview of the Haemophilus Influenzae Type b Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Haemophilus Influenzae Type b Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Type b Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biological E. Limited
  • LG Life Sciences, Ltd.
  • Novartis AG
  • Nuron Biotech, Inc.
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Haemophilus Influenzae Type b Infections Overview
Therapeutics Development
Pipeline Products for Haemophilus Influenzae Type b Infections - Overview
Pipeline Products for Haemophilus Influenzae Type b Infections - Comparative Analysis
Haemophilus Influenzae Type b Infections - Therapeutics under Development by Companies
Haemophilus Influenzae Type b Infections - Therapeutics under Investigation by Universities/Institutes
Haemophilus Influenzae Type b Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Haemophilus Influenzae Type b Infections - Products under Development by Companies
Haemophilus Influenzae Type b Infections - Products under Investigation by Universities/Institutes
Haemophilus Influenzae Type b Infections - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co., Ltd
Biological E. Limited
Chongqing Zhifei Biological Products Co., Ltd.
Indian Immunologicals Limited
LG Life Sciences, Ltd.
Novartis AG
Nuron Biotech, Inc.
Panacea Biotec Limited
Sanofi Pasteur SA
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited
Haemophilus Influenzae Type b Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
diphtheria + pertussis + tetanus + hepatitis B + haemophilus influenza [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
haemophilus influenza [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
haemophilus influenzae [serotype B] + meningococcal polysaccharide [serotypes A, C, Y, W-135] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
haemophilus influenzae [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
haemophilus influenzae [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
haemophilus influenzae [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
haemophilus influenzae type b vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
haemophilus influenzae vaccine [type B] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NU-300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PR-5I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Haemophilus Influenzae Type b Infections - Recent Pipeline Updates
Haemophilus Influenzae Type b Infections - Dormant Projects
Haemophilus Influenzae Type b Infections - Product Development Milestones
Featured News & Press Releases
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
Sep 26, 2013: Takeda Submits New Drug Application in Japan for TAK-816, a Haemophilus Influenzae type b vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Haemophilus Influenzae Type b Infections, H1 2015
Number of Products under Development for Haemophilus Influenzae Type b Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by Biological E. Limited, H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by Indian Immunologicals Limited, H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by LG Life Sciences, Ltd., H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by Novartis AG, H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by Nuron Biotech, Inc., H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by Panacea Biotec Limited, H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by Sanofi Pasteur SA, H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by Sinovac Biotech Ltd., H1 2015
Haemophilus Influenzae Type b Infections - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Haemophilus Influenzae Type b Infections Therapeutics - Recent Pipeline Updates, H1 2015
Haemophilus Influenzae Type b Infections - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Haemophilus Influenzae Type b Infections, H1 2015
Number of Products under Development for Haemophilus Influenzae Type b Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Beijing Minhai Biotechnology Co., Ltd
Biological E. Limited
Chongqing Zhifei Biological Products Co., Ltd.
Indian Immunologicals Limited
LG Life Sciences, Ltd.
Novartis AG
Nuron Biotech, Inc.
Panacea Biotec Limited
Sanofi Pasteur SA
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.